Consano Bio Gains FDA Fast Track for C-1101
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BURLINGTON, Mass., August 18, 2026 Consano Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted...
NEW YORK, May 27, 2026 Yuka, the independent food and cosmetic scoring application used by more than 85 million...
BURLINGTON, Massachusetts, May 26, 2026 Consano Bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for painful...
